PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-111.83%
Both yoy net incomes decline, with VET at -135.43%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
No Data
No Data available this quarter, please select a different quarter.
-280.95%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
No Data
No Data available this quarter, please select a different quarter.
120.00%
Well above VET's 78.56% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
-169.12%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
337.21%
Growth well above VET's 78.56%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
127.13%
Well above VET's 67.75%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-0.20%
Negative yoy CFO while VET is 58.00%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
4.85%
Some CapEx rise while VET is negative at -38160.48%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-736.36%
We reduce yoy other investing while VET is 428.44%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-4.46%
Both yoy lines negative, with VET at -6.06%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-100.94%
Both yoy lines negative, with VET at -987.32%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Repurchase growth above 1.5x VET's 56.02%. David Dodd would see a strong per-share advantage if the share price is reasonably valued.